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Abstract 
Colorectal cancer is the second leading cause of cancer-
related mortality among U.S. adults. In 2004, treatment 
costs for colorectal cancer were $8.4 billion.
There is substantial evidence that colorectal cancer inci-
dence and mortality are reduced with regular screening. 
The natural history of this disease is also well described: 
most  colorectal  cancers  develop  slowly  from  preexisting 
polyps. This slow development provides an opportunity to 
intervene with screening tests, which can either prevent 
colorectal cancer through the removal of polyps or detect it 
at an early stage. However, much less is known about how 
best to implement an effective colorectal cancer screening 
program. Screening rates are low, and uninsured persons, 
low-income persons, and persons who have not visited a 
physician within a year are least likely to be screened.
Although the Centers for Disease Control and Prevention 
(CDC) has 15 years of experience supporting the National 
Breast and Cervical Cancer Early Detection Program for 
the underserved population, a similar national program for 
colorectal cancer is not in place. To explore the feasibility 
of implementing a national program for the underserved 
U.S.  population  and  to  learn  which  settings  and  which 
program models are most viable and cost-effective, CDC 
began a 3-year colorectal cancer screening demonstration 
program in 2005.
This article describes briefly this demonstration program 
and the process CDC used to design it and to select pro-
gram sites. The multiple-methods evaluation now under 
way to assess the program’s feasibility and describe key 
outcomes is also detailed. Evaluation results will be used 
to inform future activities related to organized screening 
for colorectal cancer.
Introduction 
Cancer is the second leading cause of death among U.S. 
adults, and colorectal cancer is the second leading cause 
of cancer-related deaths among U.S. men and women. In 
2004, there were 145,083 new cases of colorectal cancer, 
and 53,580 people died of the disease (1). Although colorec-
tal cancer affects both sexes and all races, men, African 
Americans, and Alaska Natives have disproportionately 
high incidences and mortality rates of colorectal cancer (2). 
In addition, colorectal cancer is expensive to treat: in 2004, 
the national cost of medical treatment for this disease was 
$8.4 billion (3).
Most colorectal cancers develop slowly from pre-existing 
polyps. This slow development provides an opportunity to 
intervene with screening tests, which can either prevent 
colorectal cancer through the removal of polyps or detect it 
at an early stage (4). Substantial scientific evidence shows 
that the incidence and mortality are reduced by regular 
screening (5-10). However, screening rates have been slow 
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to increase (11), and it is not clear how best to implement an 
effective colorectal cancer screening program that reaches 
the people most in need. Uninsured persons, low-income 
persons, or those who have not seen a physician within the 
previous year are least likely to be screened (11).
The Centers for Disease Control and Prevention (CDC) 
has 15 years of experience supporting the National Breast 
and Cervical Cancer Early Detection Program (NBCCEDP) 
for the medically underserved population, but a similar 
national program for colorectal cancer is not in place (12). 
The NBCCEDP uses a comprehensive approach to breast 
and  cervical  cancer  control,  which  includes  providing 
early detection services, educational activities, public and 
private  partnerships,  and  quality  assurance  measures. 
Clinically, screening for colorectal cancer is more complex 
than screening for either breast or cervical cancer because 
several screening tests are acceptable, each with a differ-
ent recommended interval and each performed by differ-
ent types of health care specialists. To understand better 
how to structure and implement population-level colorec-
tal  cancer  screening  and  to  explore  which  settings  and 
program models are most viable and cost-effective, CDC 
began a 3-year colorectal cancer screening demonstration 
program in 2005. It was designed for low-income persons 
aged 50 to 64 years who are underinsured or uninsured for 
colorectal cancer screening.
This  article  describes  briefly  the  process  used  to 
establish  the  CDC-funded  Colorectal  Cancer  Screening 
Demonstration Program and the tools developed to imple-
ment this program. In accompanying reports in this issue 
of Preventing Chronic Disease (13-15), we present case-
study  and  cost-study  evaluation  findings  from  the  pro-
gram start-up period, which we defined as beginning when 
the demonstration sites received their initial funds and 
ending when the screening itself began. Future reports 
will include evaluation results from the implementation 
phase of the program.
Program Planning Process 
In the summer of 2004, CDC held two meetings with 58 
invited stakeholders, including clinicians and health sci-
entists from CDC, other federal health agencies, partner 
organizations such as the American Cancer Society and 
Prevent  Cancer  Foundation,  state  health  departments, 
and health systems such as managed care organizations. 
Also in attendance were representatives from Australia, 
the United Kingdom, and Italy, many with experience in 
organized  colorectal  cancer  screening  programs.  During 
these stakeholder meetings, we used published data, the 
combined experience of meeting attendees, and consensus 
opinion to make key decisions that helped define the dem-
onstration program. These decisions included:
Applicants  for  funds  to  implement  a  screening 
program could be any nonprofit medical entity that 
offered  services  to  low-income  persons  who  are 
underinsured for colorectal cancer screening.
When possible, screening programs would be flex-
ible  in  their  structure  and  design  so  they  could 
meet the needs of the community they intended to 
serve.
Applicants would need to actively collaborate with 
their  state’s  CDC-funded  Comprehensive  Cancer 
Control Program.
Because the U.S. Preventive Services Task Force 
(USPSTF)  (16)  recommends  four  screening  tests 
with no one “best” test recommended, applicants 
proposing a screening program could choose which 
colorectal cancer screening tests to offer as long as
•  The selected test or tests are recommended by 
USPSTF.
•  The applicant has the capacity to offer the select-
ed test or tests.
Providers within each selected program would be 
reimbursed  for  screening  and  diagnostic  tests  at 
the Medicare rate.
The focus of the screening programs would be on 
people aged 50 to 64 at average risk for colorectal 
cancer; younger persons would be eligible if they 
are at increased risk.
•  Persons at increased risk for colorectal cancer 
because of a personal or family history of this 
disease  would  be  eligible  to  receive  screening 
services.
•  Persons  with  colorectal  cancer  symptoms  or 
at  high  risk  of  colorectal  cancer  because  they 
already  have  inflammatory  bowel  disease  or 
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to  receive  services,  because  these  conditions 
require frequent specialized care.
Programs would need to convene a local medical 
advisory board to address ongoing clinical issues.
As with the NBCCEDP, CDC funds would not be 
used for cancer treatment. To be eligible for con-
sideration, applicants had to identify, in advance, 
sources that would provide treatment services for 
1) cancers detected through the screening program 
and 2) complications that may arise during screen-
ing and diagnostic procedures.
Site Selection and Program Features 
Of the 39 applicants who competed for funds to start 
a  demonstration  project,  5  were  selected  and  awarded 
a combined $2.1 million for year 1 of a 3-year program 
beginning  in  2005.  The  successful  applicants  were  the 
Maryland  Department  of  Health  and  Mental  Hygiene; 
Missouri  Department  of  Health  and  Senior  Services; 
Nebraska  Department  of  Health  and  Human  Services; 
Public Health – Seattle & King County, Washington; and 
Stony Brook University Medical Center, New York. The 
program’s structure and the screening tests selected for 
the program are described in the Figure.
Each of the five programs is described in this issue of 
Preventing Chronic Disease (14). Program components in 
the five selected sites include clinical services (screening, 
surveillance,  and  diagnostic  services),  patient  support, 
data collection and tracking, program management, public 
education and outreach, quality services measures, part-
nerships, and evaluation of program process and effective-
ness. A multidisciplinary CDC team worked closely with 
the  five  selected  sites  during  their  start-up;  the  team 
included  physicians,  public  health  advisors,  epidemi-
ologists, program analysts, evaluators, health economists, 
data consultants, and health communications specialists.
Materials Developed for the Colorectal 
Cancer Screening Program 
During  the  start-up  phase,  which  ranged  from  9  to 
11  months,  CDC  staff  and  program  staff  at  each  site   
collaborated  to  develop  the  program’s  materials  and 
components.  These  include  policies,  a  set  of  standard 
data elements (colorectal cancer clinical data elements or 
CCDEs), a data user’s manual, data collection forms, a 
readiness checklist, a cost-assessment tool, and an evalu-
ation plan. The cost-assessment tool and evaluation plan 
are described in another article in this issue of Preventing 
Chronic Disease (15). The readiness checklist, program 
policies, CCDEs, and data users’ manual are available at 
http://www.cdc.gov/cancer/colorectal/what_cdc_is_doing/
demonstration/.  Data  collection  forms  were  designed 
individually by each program site and are available on 
request.
Program policies 
CDC  created  a  policy  manual  for  this  demonstration 
program. Each site also created its own individual poli-
cies, which usually mirrored the policies that CDC creat-
ed for the overall program. Policies were developed on the 
following topics: 1) patient eligibility, 2) reimbursement, 
3) reporting adverse events, 4) collecting and reporting 
data, and 5) medical advisory committees. A series of sup-
porting documents to accompany the policy manual were 
developed by CDC in collaboration with all sites. These 
documents include guidelines for patient eligibility and 
ineligibility, reimbursable clinical services, data reporting 
requirements and schedules, and service quality indica-
tors.  These  indicators  were  developed  to  capture  data 
on the characteristics of the population being served by 
the program, the completeness of clinical follow-up and 
treatment,  and  the  timeliness  of  clinical  follow-up  and 
treatment.
Colorectal Cancer Clinical Data Elements 
The  CCDEs  were  developed  by  CDC,  program  sites, 
and two external clinical experts to ensure that informa-
tion collected about clients’ demographic characteristics, 
screening history, risk factors, screening and diagnostic 
tests, final diagnosis, and treatment would be consistent 
and  complete.  These  data  will  be  used  to  monitor  the 
extent to which the five demonstration sites achieve the 
objectives of the demonstration project. They will also be 
used  to  guide  future  policy  and  program  development. 
CDC provided technical assistance on data management 
and  reporting  to  each  of  the  five  sites  through  routine 
communication  and  through  tools  that  promote  stan-
dard reporting, including a communication Web site for 
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Maryland Department of Health and Mental Hygiene 
• Site of the colorectal cancer screening program: Baltimore
• Service delivery network: five hospitals
• Screening test offered: primary screening with colonoscopy
Missouri Department of Health and Senior Services
• Site of the colorectal cancer screening program: St. Louis
• Service delivery network: A specialty care health provider network, a uni-
versity hospital,  and federally qualified health centers
• Screening tests offered: for persons at average risk for colorectal cancer, 
primary screening with guaiac-based fecal occult blood test (FOBT) with 
colonoscopy for follow-up of positive FOBTs; for people at high risk for 
colorectal cancer, primary screening with colonoscopy
• Focus on African Americans
Nebraska Department of Health and Human Services 
• Site of the colorectal cancer screening program: statewide 
• Service delivery network: state health department and physician prac-
tices; some providers already in the National Breast and Cervical Cancer 
Early Detection Program
• Screening tests offered: for persons at average risk for colorectal cancer, 
primary screening with guaiac-based fecal occult blood test (FOBT) with 
colonoscopy for follow-up of positive FOBTs; for people at high risk for 
colorectal cancer, primary screening with colonoscopy
Public Health – Seattle & King County, Washington
• Site of the colorectal cancer screening program: King, Clallam, and 
Jefferson counties 
• Service delivery network: primary care clinics and physician practices; 
some providers already in the National Breast and Cervical Cancer Early 
Detection Program
• Screening tests offered: for persons at average risk for colorectal cancer, 
primary screening with guaiac-based fecal occult blood test (FOBT) with 
colonoscopy for follow-up of positive FOBTs; for people at high risk for 
colorectal cancer, primary screening with colonoscopy
• Focus on American Indians, Alaska Natives and African Americans
Stony Brook University Medical Center/SUNY, New York
• Site of the colorectal cancer screening program: Suffolk County, New 
York
• Service delivery network: Stony Brook University Medical Center 
with referrals from clinics associated with the Suffolk County Health 
Department
• Screening test offered: Primary screening with colonoscopy
Figure. Colorectal Cancer Demonstration Screening Sites, 2005–2008 
Note: All programs provide screening and follow-up services to low-income 
persons aged 50–6 years, who are underinsured or uninsured for colorec-
tal cancer. In addition, some programs focus on a specific demographic 
subgroup. Visit the online version of this article to view the interactive ver-
sion of this map. This page is included as a service to PDF readers.program participants, an extensive data dictionary, and 
software to validate the data set being submitted. Because 
of the short time frame and limited number of awardees 
participating in the program, we did not provide a stan-
dard data management system. 
Quality assurance 
Several measures were taken to emphasize the impor-
tance of delivering high-quality clinical services. Programs 
were made aware of important quality issues, including 
the  frequent  and  inappropriate  use  of  in-office  rather 
than at-home fecal occult blood tests (FOBT) (17), wide 
variation in adenoma detection rates among endoscopists, 
and  too-frequent  surveillance  following  polyp  detection 
(18).  Teleconferences  were  conducted  with  CDC  staff,   
endoscopists  at  all  five  sites,  and  a  leading  expert  in 
assessing the quality of colorectal cancer screening about 
issues  of  quality  and  colonoscopy  reporting  guidelines. 
Programs  and  their  participating  endoscopists  were 
encouraged to monitor their performance and follow the 
new  standard  colonoscopy  reporting  system  (CO-RADS) 
(19),  which  specifies  which  elements  should  be  includ-
ed  in  colonoscopy  reports,  provides  a  standard  method   
for  reporting  them,  and  specifies  the  key  quality  indi-
cators  that  endoscopists  should  monitor  periodically.   
The CCDEs include several factors that allow the qual-
ity of endoscopic services to be measured (e.g., whether   
the  bowel  preparation  was  adequate,  whether  the   
cecum  was  reached,  whether  polyps  were  completely 
removed).
Public education materials 
CDC’s Screen for Life: National Colorectal Cancer Action 
Campaign (SFL) (http://www.cdc.gov/cancer/colorectal/sfl/) 
is a multimedia campaign that promotes colorectal cancer 
screening for adults aged 50 years or older. Programs were 
not  required  to  use  SFL  materials,  but  materials  that 
could be adapted for local use were developed by CDC staff 
and made available to the five programs. During start-up, 
two sites used the SFL materials and worked with CDC 
to adapt the SFL logo for their own program’s use. Later, 
a third program elected to use SFL materials for patient 
education.
Readiness checklist 
CDC  developed  a  readiness  checklist  http://www.cdc.
gov/cancer/colorectal/what_cdc_is_doing/demonstration/   
to  be  used  during  start-up  to  assist  CDC  and  the  five 
sites to monitor progress toward implementing the pro-
gram. The items in the checklist corresponded to program 
components  and  include  providing  screening  and  diag-
nostic follow-up services, public education and outreach, 
data collection and tracking, patient support, partnership 
development and maintenance, quality assurance and pro-
fessional development, and program management.
Evaluation 
A  comprehensive  evaluation  of  the  colorectal  cancer 
screening  program  is  being  conducted.  It  will  provide 
information to guide our next steps. Evaluators engaged 
program and CDC stakeholders in developing a multisite 
and multiple-method evaluation to assess the program’s 
implementation,  outcomes,  and  efficiencies.  Qualitative 
and  quantitative  evaluation  approaches  will  be  used  1) 
to analyze patient screening and diagnostic services, 2) to 
determine cost and cost-effectiveness, and 3) to conduct a 
longitudinal multiple-case study.
State Programs
Colorectal cancer screening is rapidly becoming a prior-
ity at the local, state, and national levels. Several states   
(e.g., New York, Maryland) have long-standing programs; 
other  states  and  cities  (e.g.,  Colorado,  New  York  City) 
recently  began  colorectal  cancer  screening;  and  oth-
ers (e.g., Iowa, Wyoming) are planning to allocate new 
resources for organized colorectal cancer screening pro-
grams. CDC is working closely with the five demonstra-
tion program sites and communicating with other local 
and state partners who are taking steps toward establish-
ing local or state programs so that lessons learned can be 
disseminated  widely.  Several  pieces  of  legislation  have 
been introduced into the U.S. Congress that, if passed, 
would  establish  a  national  colorectal  cancer  screening 
program.
Program  activities  for  the  demonstration  sites  will 
continue  through  August  2008.  The  evaluation  findings 
published  in  this  issue  of  Preventing  Chronic  Disease   
(13-15) and findings to be reported from the implemen-
tation phase of the demonstration program will be used   
to  make  adjustments  during  the  demonstration  period   
and to guide emerging programs and larger future efforts.
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